编辑丨王多鱼 排版丨水成文 循环游离 RNA （cfRNA） 是一类存在于血液中的短片段 RNA，被认为来自 机体细胞凋亡、组织更新或外泌体释放。然而，cfRNA 易被 RNA 酶降解、含量低、 片段短，长期以来它并不被视为液体活检的理想材料。 2025 年 7 月 8 日， 芝加哥大学 何川 教授团队、 香港科技大学 张理升 教授团队等 （ 芝加哥大学博士生 鞠成威 为第一作者） 在 Nature Biotechnology 期刊 发表了题为： Modifications of microbiome-derived cell-free RNA in plasma discriminates colorectal cancer samples 的研究论文。 其中，微生物组来源的 cfRNA 中的 RNA 修饰模式能准确反映宿主微生物群的活动，研究团队在结直肠癌患者和 非癌对照者血浆样本中进行了 LIME-seq 分 析，结果显示， 结直肠癌患者血浆中多种微生物来源的 cfRNA 甲基化水平显著升高，能够精准区分癌症患者与非癌个体。此外，研究团队在胰腺癌患者样本中 观察到了同样的 微生物来源的 cfRNA 甲基 ...

Group 1: Market Performance - Energy sector ETFs rose by 2.69%, while semiconductor ETFs increased by 1.33%. Other sectors such as biotechnology, regional banks, and the banking sector saw gains of at least 0.7%, whereas consumer discretionary ETFs fell by 0.34%, internet stock indices dropped by 0.77%, and financial sector ETFs decreased by 0.89% [1] - In the S&P 500 energy sector, companies like Devon Energy, Halliburton, APA, Occidental Petroleum, Hess Corporation, and Baker Hughes saw increases of at least 4.21%, with Diamondback Energy ranking fifth among Nasdaq 100 constituents [1] Group 2: ETF Details - Energy ETF closed at $88.50, up by 2.68%, with a total market value of $22.163 billion, reflecting a year-to-date increase of 4.97% [2] - Semiconductor ETF closed at $283.48, up by 1.33%, with a total market value of $3.351 billion, showing a year-to-date increase of 17.06% [2] - Biotechnology ETF closed at $129.33, up by 0.94%, with a total market value of $10.269 billion, down by 2.09% year-to-date [2] - Regional bank ETF closed at $63.15, up by 0.91%, with a total market value of $5.270 billion, reflecting a year-to-date increase of 6.06% [2] - Banking sector ETF closed at $58.46, up by 0.69%, with a total market value of $4.525 billion, showing a year-to-date increase of 6.87% [2] - Consumer discretionary ETF closed at $217.66, down by 0.34%, with a total market value of $27.339 billion, reflecting a year-to-date decrease of 2.51% [2] - Financial sector ETF closed at $52.21, down by 0.89%, with a total market value of $58.112 billion, showing a year-to-date increase of 8.79% [2]

Core Viewpoint - The announcement of new tariffs by the Trump administration has significantly impacted global financial markets, leading to sharp declines in major stock indices and increased volatility in currencies and commodities [1][3][6]. Tariff Impact - Starting August 1, the U.S. will impose a 25% tariff on all goods imported from Japan and South Korea, with additional punitive tariffs ranging from 25% to 40% on 12 other countries, including South Africa and Kazakhstan [3][6]. - The average tariff rate is expected to exceed the current baseline of 10%, raising concerns about the potential for further trade tensions [3]. Market Reaction - Following the tariff announcement, the Dow Jones Industrial Average fell by 422 points (0.94%), while the S&P 500 index dropped below 6230 points, indicating a widespread sell-off in the markets [1][3]. - The VIX index, a measure of market volatility, surged by 1.77, reflecting heightened investor anxiety [1]. Sector Performance - The technology sector faced significant losses, with major companies like Tesla, Apple, and Google experiencing declines of over 1.5%, while the automotive sector was particularly hard hit, with Nissan and Toyota ADRs dropping nearly 4% [3][4]. - The "Trump Tariff Losers" index, which tracks companies sensitive to tariffs, fell by 1.35%, highlighting the broader impact on affected industries [3]. Capital Movements - In contrast to the overall market downturn, Chinese concept stocks showed resilience, with the Nasdaq Golden Dragon China Index rising by 0.59%, driven by significant gains in companies like CloudMi Technology and BitOrigin [4]. - Gold prices experienced volatility, initially dropping below $3,300 before recovering, indicating a flight to safety among investors [6]. Economic Outlook - The Federal Reserve's likelihood of interest rate cuts has increased, with probabilities exceeding 50% for a September reduction, as economic indicators suggest that the impact of tariffs may be less severe than initially feared [7]. - Analysts are closely monitoring the potential for further tariff escalations, particularly from the EU and India, which could exacerbate market volatility [7].

来源：环球网 【环球网科技综合报道】7月8日消息，据中科院官方消息，中国科学院天津工业生物技术研究所首次通 过构建体外生物转化系统，实现甲醇合成蔗糖，突破了依赖自然种植甘蔗和甜菜获取蔗糖的局限，为更 多糖分子的生物合成提供研究思路。 这项研究的意义远不止于成功合成蔗糖，它搭建起的体外生物转化平台，恰似一把能开启"人工糖世 界"大门的密钥。科研人员借助该平台，不仅合成了低分子量淀粉、纤维寡糖等功能糖产品，而且产物 得率颇高，这些产品可广泛应用于食品和饲料领域。 科研人员所开发的体外生物合成系统，能够与电催化或热催化还原二氧化碳的过程相耦合，真正达成了 从二氧化碳从头开始转化合成蔗糖的目标。 该研究以二氧化碳为核心原料，实现了将其人工转化为食品和化学品。未来，科研人员计划在系统中引 入不同的酶催化剂，以合成自然界中含量稀少却功效独特的糖分子，这一举措对推动绿色发展或将产生 积极影响。（青山） 此前，中国科学院大连化学物理研究所已凭借化学手段，成功将二氧化碳固定并合成甲醇，这一过程被 誉为"液态阳光"的制造工艺。 倘若在完成二氧化碳固定之后，能够从工业废弃物里获取甲醇等低碳分子，再借助生物手段将它们转化 为糖分子， ...

Group 1 - The A-share market showed mixed results with the Chinese Securities Trading Service Hong Kong Biotechnology Index (CESHKB) declining by 2.61% to 7650.23 points, with a trading volume of 9.469 billion [1] - Over the past month, the CESHKB has increased by 15.23%, 28.86% over the last three months, and 75.31% year-to-date [1] - The CESHKB is compiled by the China Securities Index Co., Ltd. under the commission of the China Securities Trading Service Co., Ltd., aiming to reflect the overall performance of biotechnology companies listed in Hong Kong [1] Group 2 - The top ten holdings of the CESHKB include: CanSino Biologics (12.33%), Innovent Biologics (9.95%), WuXi Biologics (9.17%), 3SBio (8.66%), BeiGene (8.57%), Zai Lab (5.79%), WuXi AppTec (5.63%), Kelun-Biotech (5.28%), Ascentage Pharma-B (4.19%), and Kingstar Biotech (4.11%) [1] - The CESHKB's holdings are entirely composed of companies listed on the Hong Kong Stock Exchange, with a 100% representation in the healthcare sector [2]

Market Overview - Major industry ETFs in the US stock market mostly declined, with the Consumer Discretionary ETF dropping over 1%, the Semiconductor ETF falling nearly 1%, and the Biotechnology Index ETF decreasing by 0.7% [1] ETF Performance - Consumer Discretionary ETF (US XLY) current price: $218.19, down by $3.02 (-1.37%), with a trading volume of 115,000 shares and a total market value of $27.405 billion, year-to-date performance down by 2.27% [2] - Semiconductor ETF (US SMH) current price: $281.22, down by $2.40 (-0.85%), with a trading volume of 229,900 shares and a total market value of $3.324 billion, year-to-date performance up by 16.13% [2] - Biotechnology Index ETF (US IBB) current price: $129.11, down by $0.89 (-0.68%), with a trading volume of 22,713 shares and a total market value of $10.251 billion, year-to-date performance down by 2.26% [2] - Energy ETF (US XLE) current price: $86.56, down by $0.47 (-0.54%), with a trading volume of 1.4898 million shares and a total market value of $21.677 billion, year-to-date performance up by 2.67% [2] - Technology Sector ETF (US XLK) current price: $255.63, down by $1.33 (-0.52%), with a trading volume of 203,700 shares and a total market value of $81.304 billion, year-to-date performance up by 10.31% [2] - Healthcare ETF (US XLV) current price: $134.89, down by $0.61 (-0.45%), with a trading volume of 353,700 shares and a total market value of $25.813 billion, year-to-date performance down by 1.10% [2] - Global Technology ETF (US IXN) current price: $92.93, down by $0.40 (-0.43%), with a trading volume of 7,225 shares and a total market value of $1.301 billion, year-to-date performance up by 9.86% [2] - Consumer Staples ETF (US XLP) current price: $81.87, down by $0.31 (-0.38%), with a trading volume of 847,500 shares and a total market value of $13.854 billion, year-to-date performance up by 5.42% [2] - Internet ETF (US FDN) current price: $268.40, down by $0.62 (-0.23%), with a trading volume of 5,447 shares and a total market value of $178.22 billion, year-to-date performance up by 10.38% [2] - Utilities ETF (US XLU) current price: $81.75, down by $0.09 (-0.11%), with a trading volume of 672,400 shares and a total market value of $11.868 billion, year-to-date performance up by 9.53% [2] - Global Airlines ETF (US JETS) current price: $24.13, up by $0.01 (+0.03%), with a trading volume of 31,918 shares and a total market value of $76.0004 million, year-to-date performance down by 4.82% [2] - Banking ETF (US KBE) current price: $58.86, up by $0.04 (+0.07%), with a trading volume of 62,373 shares and a total market value of $4.556 billion, year-to-date performance up by 7.60% [2] - Financials ETF (US XLF) current price: $53.24, up by $0.05 (+0.09%), with a trading volume of 1.5935 million shares and a total market value of $59.259 billion, year-to-date performance up by 10.94% [2] - Regional Banks ETF (US KRE) current price: $63.36, up by $0.13 (+0.21%), with a trading volume of 282,500 shares and a total market value of $5.288 billion, year-to-date performance up by 6.41% [2]

Company Overview - Sido Medical Co., Ltd. is an innovative pharmaceutical company focused on oncology and chronic disease treatment, with a vision to "help cancer patients live longer and better" [2] - The company has a product line of 12 innovative drugs with differentiated clinical value, 8 of which are in clinical development or commercialization stages [2] - The first subcutaneous PD-L1 monoclonal antibody, Envida, has been approved for sale by the National Medical Products Administration [2] - The company utilizes its proprietary mRNA research platform and tumor genomic big data AI analysis platform to develop a series of mRNA products [2] - Sido Medical has established capabilities across drug discovery, preclinical research, clinical development, regulatory submission, and commercialization [2] Financial Performance - As of December 31, 2024, Sido Medical reported total revenue of 446 million yuan, a year-on-year decrease of 29.81% [1] - The company recorded a net profit attributable to shareholders of -183 million yuan, an increase of 65.19% year-on-year [1] - The gross profit margin stands at 91.79%, with a debt-to-asset ratio of 42.14% [1] Market Position and Valuation - The average price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology industry is 1.96 times, with a median of 6.18 times [1] - Sido Medical's P/E ratio is -5.69 times, ranking 132nd in the industry [1] - Comparatively, other companies in the industry have P/E ratios such as: Qingdao Haier Biomedical (0.86), Kingsray Biotechnology (1.43), Dongrui Pharmaceutical (3.06), and Jilin Changlong Pharmaceutical (6.00) [1]

Core Insights - PwC has successfully assisted five outstanding companies from mainland China in their IPOs on the Hong Kong Stock Exchange, showcasing strong performance [1] - The companies include Yunzhisheng, Yingtong Holdings, Cao Cao Travel, Rongda Hezhong, and Bokan Vision, each representing different sectors such as AI, consumer goods, ride-sharing, technology solutions, and ophthalmic biotechnology [1][3][4] Company Summaries - Bokan Vision Pharmaceutical Co., Ltd. was listed on July 3, 2025, under stock code 2592, focusing on developing treatments for chronic eye diseases with two core self-developed products [1] - Rongda Hezhong Technology Group Co., Ltd. was listed on June 10, 2025, under stock code 9881, providing technology solutions and serving as an important player in the market [3] - Cao Cao Travel, a ride-hailing platform incubated by Geely Group, was listed on June 25, 2025, under stock code 02643, becoming a strong competitor in the industry [3] - Yingtong Holdings, the largest perfume group in China (including Hong Kong and Macau), was listed on June 26, 2025, under stock code 6883, focusing on brand expansion and distribution [3] - Yunzhisheng Intelligent Technology Co., Ltd. was listed on June 30, 2025, under stock code 9678, specializing in AI solutions with a focus on enhancing operational efficiency and decision-making [4]

Core Insights - Chengdu's "免申即享" (No Application, Immediate Enjoyment) policy is effectively streamlining the process for companies to receive financial support without the need for extensive applications, enhancing the business environment [1][4][5] Group 1: Impact on Companies - The "免申即享" funding has provided immediate financial relief to companies like Shuyun Tianfu Panda Creative Cultural Tourism Co., which has alleviated cash flow pressures and boosted long-term confidence in project development [3][4] - Sichuan Jiuyuan Yinhai Software Co. has also benefited from the policy, receiving funds without the previous burdens of application processes, which has improved operational efficiency and innovation confidence [3][4] - The policy has transformed the traditional approach of "companies seeking policies" to "policies seeking companies," significantly reducing the time and effort required for funding applications [4][5] Group 2: Government Initiatives - Chengdu's government has established a mechanism to prioritize the "免申即享" approach in new policy formulations, with a current implementation rate of 30% for new business support policies [5][6] - The city has committed to enhancing the feasibility assessment of the "免申即享" approach in new policies, ensuring that a higher percentage of support measures are accessible without cumbersome application processes [5][6] - Ongoing reforms aim to further increase the proportion of "免申即享" policies, improving the overall experience and satisfaction of businesses with government support [6]

一周IPO动态，覆盖港股、美股、A股。 本文为IPO早知道原创 作者｜C叔 微信公众号｜ipozaozhidao 云知声 港股｜挂牌上市 据IPO早知道消息，云知声智能科技股份有限公司（以下简称"云知声"）于2025年6月30日正式 以"9678"为股票代码在港交所主板挂牌上市，成为"港股AGI第一股"。 作为中国AGI技术的先行者，成立于2012年的云知声在以深度学习模型发布为标志的人工智能自然 语言处理取得突破后不久，即利用自己在交互式AI方面的研发专业知识和自成立以来获得的市场洞 察力，推出首个基于BERT的大语言模型UniCore，作为自己的中心技术平台云知大脑的初始核心算 法模型，并为广泛的垂直行业的客户赋能一系列AI解决方案。 2016年，云知声战略性地开始建立Atlas AI基础设施，其基于云知声的智算集群，高效地为机器学 习任务动态调度强大的算力，同时这也前沿AI模型的开发、优化和商业化提供重要支撑。目前，云 知声的智算集群拥有超过184 PFLOPS的计算能力，以及超过10PB的存储容量。在过去几年 UniCore的演进和优化的基础上，云知声于2023年推出了一个拥有600亿个参数的自有大语 ...